Can a common cholesterol drug boost liver cancer treatment?
NCT ID NCT01903694
Summary
This study tested whether adding a cholesterol-lowering drug (pravastatin) to the standard liver cancer drug sorafenib could help patients live longer. It involved 474 adults with advanced liver cancer who were not candidates for surgery or other curative treatments. The main goal was to see if the drug combination improved survival compared to sorafenib alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILD-PUGH A HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079, France
Conditions
Explore the condition pages connected to this study.